We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+22.21%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$303M
AUM Growth
-$35.4M
(-10%)
Cap. Flow
-$54.1M
Cap. Flow
% of AUM
-17.87%
Top 10 Holdings %
Top 10 Hldgs %
52.11%
Holding
73
New
15
Increased
24
Reduced
14
Closed
16
Top Buys
| 1 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$8.57M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$6.77M |
| 3 |
ONC
BeOne Medicines Ltd
ONC
|
+$5.18M |
| 4 |
AKRO
Akero Therapeutics
AKRO
|
+$3.9M |
| 5 |
Vir Biotechnology
VIR
|
+$3.77M |
Top Sells
| 1 |
Axsome Therapeutics
AXSM
|
+$8.48M |
| 2 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$8.4M |
| 3 |
Pfizer
PFE
|
+$8.16M |
| 4 |
Johnson & Johnson
JNJ
|
+$7.75M |
| 5 |
TG Therapeutics
TGTX
|
+$7.1M |
Sector Composition
| 1 | Healthcare | 91.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $25M | 8.24% |
300,000
| – | – |
|
|
2
TG Therapeutics
TGTX
$8.4B
| $20.5M | 6.77% |
825,000
-275,000
| -25% | -$7.1M |
|
3
MoonLake Immunotherapeutics
MLTX
$1.64B
| $16.8M | 5.56% |
330,000
+135,000
| +69% | +$3.63M |
|
|
AKRO
4
DELISTED
Akero Therapeutics
AKRO
| $16.8M | 5.55% |
360,000
+85,000
| +31% | +$3.9M |
|
|
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
| $16.4M | 5.41% |
180,000
+15,380
| +9% | +$1.33M |
|
6
Vaxcyte
PCVX
$8.12B
| $14M | 4.62% |
280,000
+55,000
| +24% | +$2.61M |
|
|
RVNC
7
DELISTED
Revance Therapeutics, Inc.
RVNC
| $13.3M | 4.39% |
525,000
+275,000
| +110% | +$8.57M |
|
|
8
Madrigal Pharmaceuticals
MDGL
$12.8B
| $12.7M | 4.19% |
55,000
+25,000
| +83% | +$6.77M |
|
9
Amylyx Pharmaceuticals
AMLX
$1.97B
| $11.9M | 3.92% |
550,000
+75,000
| +16% | +$2.03M |
|
10
Viking Therapeutics
VKTX
$4.31B
| $10.5M | 3.48% |
650,000
+50,000
| +8% | +$1.05M |
|
11
Sarepta Therapeutics
SRPT
$1.82B
| $9.73M | 3.21% |
85,000
+25,000
| +42% | +$3.22M |
|
12
Ascendis Pharma A/S
ASND
$17.1B
| $8.93M | 2.95% |
100,000
-10,000
| -9% | -$870K |
|
|
RETA
13
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $8.67M | 2.86% |
85,000
+15,000
| +21% | +$1.42M |
|
|
14
Axsome Therapeutics
AXSM
$11.8B
| $7.9M | 2.61% |
110,000
-115,000
| -51% | -$8.48M |
|
15
Syndax Pharmaceuticals
SNDX
$2.02B
| $7.33M | 2.42% |
350,000
+25,000
| +8% | +$520K |
|
|
MRTX
16
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $7.23M | 2.39% |
200,000
+60,000
| +43% | +$2.47M |
|
17
Xenon Pharmaceuticals
XENE
$6.6B
| $7.12M | 2.35% |
185,000
-15,000
| -8% | -$596K |
|
18
Cogent Biosciences
COGT
$6.68B
| $6.81M | 2.25% |
575,000
+25,000
| +5% | +$287K |
|
19
Protagonist Therapeutics
PTGX
$9.06B
| $6.21M | 2.05% |
225,000
| – | – |
|
20
Viridian Therapeutics
VRDN
$1.99B
| $5.71M | 1.88% |
240,000
+65,000
| +37% | +$1.67M |
|
21
Biomea Fusion
BMEA
$92.5M
| $4.17M | 1.38% |
190,000
+70,000
| +58% | +$2.19M |
|
22
Incyte
INCY
$23.4B
| $4.05M | 1.34% |
65,000
-10,000
| -13% | -$668K |
|
|
ONC
23
BeOne Medicines Ltd
ONC
$32.4B
| $4.01M | 1.32% |
+22,500
| New | +$5.18M |
|
|
AMAM
24
DELISTED
Ambrx Biopharma Inc
AMAM
| $3.92M | 1.29% |
238,225
-11,775
| -5% | -$148K |
|
|
25
Vir Biotechnology
VIR
$1.59B
| $3.68M | 1.21% |
+150,000
| New | +$3.77M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q2 2023 Portfolio in Review
As of Q2 2023, Ghost Tree Capital held 73 positions worth $303M, down 10% from $338M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Ghost Tree Capital withdrew a net $54.1M in Q2 2023, closing 16 positions and reducing 14 holdings. Its most notable exit was CTI BioPharma Corp. (DE) Common Stock, an estimated $8.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 78% a quarter earlier.
Against the trend, Ghost Tree Capital opened a new position in BeOne Medicines Ltd worth $4.01M.
- Ghost Tree Capital's largest Q2 2023 buy was BeOne Medicines Ltd: 22,500 shares worth $4.01M.
- Ghost Tree Capital added most to Revance Therapeutics, Inc. in Q2 2023, an estimated $8.57M increase.
- Ghost Tree Capital's biggest Q2 2023 reduction was Axsome Therapeutics, cutting an estimated $8.48M.
- Ghost Tree Capital fully exited CTI BioPharma Corp. (DE) Common Stock in Q2 2023, selling an estimated $8.4M.
- Ghost Tree Capital's ten largest holdings make up 52% of its $303M portfolio in Q2 2023.
- Ghost Tree Capital opened 15 new positions and closed 16 in Q2 2023.
- Ghost Tree Capital's portfolio value fell 10% quarter-over-quarter to $303M.
Based on Ghost Tree Capital's 13F filing for Q2 2023, filed 14 Aug 2023.